Schizophrenia is not caused by simply having too much dopamine. The real picture is more nuanced: people with schizophrenia appear to have dopamine levels that are too high in some brain regions and too low in others. This imbalance, rather than a straightforward excess, is what drives the wide range of symptoms the condition produces.
The Original Dopamine Hypothesis
The idea that schizophrenia comes from excess dopamine dates back to the 1960s and 1970s. Researchers noticed that drugs boosting dopamine (like amphetamines) could trigger psychotic symptoms in healthy people, and that the first effective antipsychotic medications worked by blocking dopamine receptors. The logical conclusion seemed simple: too much dopamine causes schizophrenia.
That early model wasn’t wrong so much as incomplete. It could explain hallucinations and delusions, but it couldn’t account for the other half of schizophrenia: the withdrawal, flat emotions, and cognitive problems that often cause the most long-term disability. If all symptoms came from excess dopamine, blocking it should fix everything. It doesn’t.
Too Much in One Place, Too Little in Another
The revised dopamine hypothesis, which is the model most researchers work with today, describes a split. In deeper, more primitive brain structures (the mesolimbic pathway, which runs through the brain’s reward and emotion centers), dopamine signaling is overactive. In the prefrontal cortex, the area responsible for planning, decision-making, and working memory, dopamine signaling is underactive.
This split maps neatly onto the two main categories of symptoms. The “positive” symptoms, things that are added to a person’s experience like hearing voices and believing things that aren’t real, correspond to excessive dopamine activity in the brain’s deeper structures. Increased dopamine there overstimulates a specific type of receptor, causing the brain to assign intense significance to random thoughts, perceptions, or external stimuli that would normally be filtered out.
The “negative” symptoms, things that are missing from a person’s experience like motivation, emotional expression, and the ability to feel pleasure, correspond to too little dopamine activity in the prefrontal cortex. This deficit impairs a different type of receptor and disrupts the higher-order thinking that depends on that brain region. These two problems are connected: research in animal models has shown the relationship is bidirectional, with excess dopamine signaling in deeper brain structures actively suppressing dopamine release in the prefrontal cortex.
What Brain Scans Actually Show
Brain imaging studies using PET scans can measure how much dopamine the brain is producing. A meta-analysis of these studies found that elevated dopamine production and release capacity in the striatum (a deep brain structure involved in movement and reward) is the primary dopamine abnormality in schizophrenia, with a large statistical effect size. Studies in drug-naive patients have consistently shown higher levels of dopamine production compared to healthy controls.
One particularly telling set of findings comes from scanning people who are considered at ultra-high risk for psychosis but haven’t yet developed it. In a study published in the American Journal of Psychiatry, researchers scanned at-risk individuals and followed them over time. The nine who later developed a psychotic disorder had significantly higher dopamine production in the striatum at the time of scanning than both healthy controls and the fifteen at-risk individuals who never became psychotic. The degree of dopamine elevation correlated with symptom severity. This is strong evidence that dopamine overproduction in specific brain regions precedes the illness rather than being a consequence of it.
Dopamine Isn’t the Whole Story
While dopamine dysregulation is central to schizophrenia, it increasingly looks like the final step in a chain rather than the root cause. The current scientific framework, sometimes called “version III” of the dopamine hypothesis, treats dopamine dysfunction as a “final common pathway” that multiple risk factors feed into.
Those risk factors are wide-ranging. Pregnancy and birth complications roughly double the risk of later developing schizophrenia. Frequent cannabis use carries about twice the risk, and heavy amphetamine use increases risk roughly tenfold. Migration, childhood trauma, and chronic stress also contribute. Animal studies have confirmed that prenatal and early-life stressors can produce lasting overactivity in the same dopamine pathways implicated in schizophrenia. Notably, these environmental risk factors each carry higher individual risk than any single gene variant identified so far.
Other neurotransmitter systems are also involved. The brain’s main excitatory signaling chemical (glutamate) and its main inhibitory one (GABA) both appear to be dysregulated in schizophrenia, particularly in circuits connecting the cortex, striatum, and thalamus. Research in patients experiencing their first psychotic episode has found an abnormal relationship between dopamine activity in the brain’s reward center and GABA levels in the cortex, a relationship that may even predict how well someone responds to initial treatment. Disrupted balance between excitation and inhibition in cortical brain networks, particularly involving a class of neurons that use GABA, is now seen as a key piece of the puzzle.
Why This Matters for Treatment
Every antipsychotic medication currently in wide use works primarily by reducing dopamine signaling, which is why these drugs are most effective against hallucinations and delusions. They target the “too much dopamine” side of the equation. This also explains their biggest limitation: they do relatively little for the negative symptoms and cognitive problems tied to too little dopamine in the prefrontal cortex.
There’s another complication. Not everyone with schizophrenia has the same dopamine profile. PET studies have found that people with treatment-resistant schizophrenia, those who don’t improve on standard antipsychotic medications, may actually have lower dopamine production than both treatment-responsive patients and healthy controls. This suggests that for a significant subset of patients, dopamine excess isn’t the primary driver of their symptoms at all, which would explain why dopamine-blocking drugs don’t help them.
This is pushing treatment research in new directions. Approaches targeting glutamate signaling, a specific type of acetylcholine receptor, and a receptor involved in regulating how much dopamine neurons release are all in development. These strategies aim to address the parts of schizophrenia that dopamine-blocking drugs miss.
The Role of Genetics
Several genes influence how the dopamine system works, and variations in these genes have been linked to schizophrenia risk. One well-studied example is the gene for an enzyme that breaks down roughly 50 to 60 percent of dopamine in the frontal cortex. A common variation in this gene reduces the enzyme’s activity by about 40 percent, which means dopamine lingers longer in the prefrontal cortex. Another involves the gene for the dopamine receptor most targeted by antipsychotic drugs. Variations in this gene affect receptor density in both the striatum and cortex, and specific versions have been associated with heightened schizophrenia risk, though which version carries risk varies across populations.
No single gene causes schizophrenia. The genetic architecture involves many small-effect variants that each nudge the dopamine system (and other systems) slightly off balance. Combined with the right environmental stressors, these nudges can accumulate into the kind of dopamine dysregulation seen in the illness.
The Bottom Line on Dopamine
Saying schizophrenia is caused by “too much dopamine” is like saying a car crash was caused by “too much speed.” It’s pointing at one visible element of a complex event. Dopamine is genuinely dysregulated in schizophrenia, and that dysregulation is measurable, predictive of who will develop psychosis, and treatable with medications that target it. But the dysregulation runs in both directions simultaneously, is driven by a web of genetic and environmental factors, and interacts with at least two other major neurotransmitter systems. The dopamine story is real. It’s just not the whole story.